Skip to content

Gadobutrol (Gadovist®) versus gadofosveset-trisodium (Vasovist®) in MR venography of the peripheral venous vasculature in deep vein thrombosis: is their a need for blood pool contrast agents?

Gadobutrol (Gadovist®) versus gadofosveset-trisodium (Vasovist®) in MR venography of the peripheral venous vasculature in deep vein thrombosis: is their a need for blood pool contrast agents? - MR Venography in deep vein thrombosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON36357
Enrollment
20
Registered
2011-06-30
Start date
2011-11-01
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep vein thrombosis

Interventions

None listed

Sponsors

Medisch Universitair Ziekenhuis Maastricht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Age between 18-65 years * Objectively documented DVT * Patient scheduled for CE-MRV * Patient able to undergo CE-MRV twice within one week * Patient is not scheduled to receive invasive treatment between both examinations

Exclusion criteria

Exclusion criteria: * Hemodynamic instability * Known allergy for gadolinium based MR contrast agents * Contra-indications for MRI * eGFR

Design outcomes

Primary

MeasureTime frame
Image quality of our current method using vasovist will be compared with image quality of the new scan sequence, both with Vasovist and Gadovist as contrast agents. Image quality will assessed both subjectively and objectively. For subjective assessment of image quality a 8-point scale is used to determine clinical suitability and influence of image artifacts. Objective assessment of image quality is performed by measuring the signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR).

Secondary

MeasureTime frame
Images quality of DSA images will be compared with MRV data using the same method.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)